Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2000 Nov;91(11):1177–1184. doi: 10.1111/j.1349-7006.2000.tb00902.x

Expression of Tumor‐rejection Antigens in Gynecologic Cancers

Shoko Tanaka 1,2, Naotake Tsuda 1,3, Kouichirou Kawano 1,3, Masaru Sakamoto 5, Takashi Nishida 3, Takashi Hashimoto 2, Shigeki Shichijo 1, Toshiharu Kamura 3, Kyogo Itoh 1,4,✉
PMCID: PMC5926290  PMID: 11092984

Abstract

We recently reported the four tumor‐rejection antigens (SART1259 SART2, SART3, and ART4) that possess tumor epitopes capable of inducing HLA‐A2402‐restricted cytotoxic T lymphocytes (CTLs) in cancer patients. This study investigated the expression of these tumor antigens in gynecologic cancers, including 33 ovarian cancers, 38 cervical cancers, and 40 endometrial cancers. SART1259 antigen was detected in 56%, 35%, and 30% of ovarian, cervical and endometrial cancers, while SART2 antigen was detected in 46%, 66%, and 30% of these cancers, respectively. Both SART3 and ART4 antigens were detectable in the majority of these gynecologic cancers tested. In contrast, none of these antigens was detectable in any of the normal ovarian and uterine tissues tested. Peripheral blood mononuclear cells (PBMCs) of HLA‐A24+ patients with gynecologic cancers were found to produce significant levels of interferon‐γ in response to HLA‐A24+ SART3+ gynecologic cancer cells after having been stimulated three times in vitro with either SART3109–118 or SART3315–323 peptide. These PBMCs lysed HLA‐A24+ SART3+ gynecologic cancer cells, but not HLA‐A24‐ SART3+ gynecologic cancer cells or HLA‐A24+ normal cells. Therefore, these four antigens and their peptides, including SART3 peptides, would be appropriate molecules for use in specific immunotherapy of HLA‐A24+ gynecologic cancer patients.

Keywords: Tumor antigen, Gynecologic cancer, Specific immunotherapy, HLA‐A24, Cytotoxic T lymphocyte

Full Text

The Full Text of this article is available as a PDF (103.1 KB).

REFERENCES

  • 1. ) Traversari , C. , Van Der Bruggen , P. , Luescher , I. F. , Lurquin , C. , Chomez , P. , Van Pel , A. , De Plaen , E. , Amar‐Costesec , A. and Boon , T.A nonapeptide encoded by human gene MAGE‐1 is recognized on HLA‐A1 by cytolytic T lymphocytes directed against tumor antigen MZ2‐E . J. Exp. Med. , 176 , 1453 – 1457 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. ) Van Der Bruggen , P. , Bestin , J. , Coulie , P. G. , De Smet , C. , Traversari , C. , Townsent , A. and Boon , T.A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3 . Eur. J. Immunol. , 24 , 3038 – 3043 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Kawakami , Y. , Eliyahu , S. , Sakaguchi , K. , Robbins , P. F. , Rivoltini , L. , Yannelli , J. R. , Appella , E. and Rosenberg , S. A.Identification of the immunodominant peptides of the MART‐1 human melanoma antigen recognized by the majority of HLA‐A2‐restricted tumor infiltrating lymphocytes . J. Exp. Med. , 180 , 347 – 352 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. ) Kawakami , Y. , Eliyahu , S. , Jennings , C. , Sakaguchi , K. , Kang , X. , Southwood , S. , Robbins , P. F. , Sette , A. , Appella , E. and Rosenberg , S. A.Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor‐infiltrating T lymphocytes associated with in vivo tumor regression . J. Immunol. , 154 , 3961 – 3968 ( 1995. ). [PubMed] [Google Scholar]
  • 5. ) Robbins , P. F. , El‐Gamil , M. , Li , Y. F. , Kawakami , Y. , Loftus , D. , Appella , E. and Rosenberg , S. A.A mutated β‐catenin gene encodes a melanoma‐specific antigen recognized by tumor infiltrating lymphocytes . J. Exp. Med. , 183 , 1185 – 1192 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. ) Robbins , P. F. , El‐Gamil , M. , Li , Y. F. , Fitzgerald , E. B. , Kawakami , Y. and Rosenberg , S. A.The intronic region of an incompletely spliced gp 100 gene transcript encodes an epitope recognized by melanoma‐reactive tumor‐infiltrating lymphocytes . J. Immunol. , 159 , 303 – 308 ( 1997. ). [PubMed] [Google Scholar]
  • 7. ) Traversari , C. , Meazza , R. , Coppolecchia , M. , Basso , S. , Verreccia , A. , Van Der Bruggen , P. , Ardizzoni , A. , Gaggero , A. and Ferrini , S.IFN‐γ gene transfer restores HLA‐class I expression and MAGE‐3 antigen presentation to CTL in HLA‐deficient small cell lung cancer . Gene Ther. , 4 , 1029 – 1035 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Van Der Bruggen , P. , Traversari , C. , Chomez , P. , Lurquin , C. , De Plaen , E. , Van Den Eynde , B. , Knuth , A. and Boon , T.A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma . Science , 254 , 1643 – 1647 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Marchand , M. , Van Baren , N. , Weynants , P. , Brichard , V. , Dreno , B. , Tessier , M. H. , Rankin , E. , Parmiani , G. , Arienti , F. , Humblet , Y. , Bourlond , A. , Vanwijck , R. , Lienard , D. , Beauduin , M. , Dietrich , P. Y. , Russo , V. , Kerger , J. , Masucci , G. , Jager , E. , De Greve , J. , Atzpodien , J. , Brasseur , F. , Coulie , P. G. , Van Der Bruggen , P. and Boon , T.Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 . Int. J. Cancer , 80 , 219 – 230 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Gaugler , B. , Van Den Eynde , B. , Van Der Bruggen , P. , Romero , P. , Gaforio , J. J. , De Plaen , E. , Lethe , B. , Brasseur , F. and Boon , T.Human gene MAGE‐3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes . J. Exp. Med. , 179 , 921 – 930 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. ) Rosenberg , S. A. , Yang , J. C. , Schwartzentruber , D. J. , Hwu , P. , Marincola , F. M. , Topalian , S. L. , Restifo , N. P. , Dudley , M. E. , Schwarz , S. L. , Spiess , P. J. , Wunderlich , J. R. , Parkhurst , M. R. , Kawakami , Y. , Seipp , C. A. , Einhorn , J. H. and White , D. E.Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma . Nat. Med. , 4 , 321 – 327 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. ) Nestle , F. O. , Alijagic , S. , Gilliet , M. , Sun , Y. , Grabbe , S. , Dummer , R. , Burg , G. and Schadendorf , D.Vaccination of melanoma patients with peptide‐ or tumor lysate‐pulsed dendritic cells . Nat. Med. , 4 , 328 – 332 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Fisk , B. , Anderson , B. W. , Gravitt , K. R. , O'Brian , C. A. , Kudelka , A. P. , Murray , J. L. , Wharton , J. T. and Ioannides , C. G.Identification of naturally processed human ovarian peptides recognized by tumor‐associated CD8+ cytotoxic T lymphocytes . Cancer Res. , 57 , 87 – 93 ( 1997. ). [PubMed] [Google Scholar]
  • 14. ) Babcock , B. , Anderson , B. W. , Papayannopoulos , I. , Castilleja , A. , Murray , J. L. , Stifani , S. , Kudelka , A. P. , Wharton , J. T. and Ioannides , C. G.Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the Notch complex . Mol. Immunol. , 35 , 1127 – 1133 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Yoshino , I. , Goedegebuure , P. S. , Peoples , G. E. , Parikh , A. S. , Di Maio , J. M. , Lyerly , H. K. , Gazder , A. F. and Eberlein , T. J.HER2/neu‐derived peptides are shared antigens among human non‐small cell lung cancer and ovarian cancer . Cancer Res. , 54 , 3387 – 3390 ( 1994. ). [PubMed] [Google Scholar]
  • 16. ) Matsumoto , H. , Shichijo , S. , Kawano , K. , Nishida , T. , Sakamoto , M. and Itoh , K.Expression of the SART‐1 antigens in uterine cancers . Jpn. J. Cancer Res. , 89 , 1292 – 1295 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. ) Shichijo , S. , Nakao , M. , Imai , Y. , Takasu , H. , Kawamoto , M. , Niiya , F. , Yang , D. , Itoh , Y. , Yamana , H. and Itoh , K.A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes . J. Exp. Med. , 187 , 277 – 288 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. ) Kikuchi , M. , Nakao , M. , Inoue , Y. , Matsunaga , K. , Shichijo , S. , Yamana , H. and Itoh , K.Identification of a SART1‐derived peptide capable of inducing HLA‐A24‐restricted and tumor‐specific cytotoxic T lymphocytes . Int. J. Cancer , 81 , 459 – 466 ( 1999. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Nakao , M. , Shichijo , S. , Imaizumi , T. , Inoue , Y. , Matsunaga , K. , Yamada , A. , Kikuchi , M. , Tsuda , N. , Ohta , K. , Takamori , S. , Yamana , S. , Fujita , H. , Yamana , H. and Itoh , K.Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL . J. Immunol. , 164 , 2565 – 2574 ( 2000. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Yang , D. , Nakao , M. , Shichijo , S. , Sasatomi , T. , Takasu , H. , Matsumoto , H. , Mori , K. , Yamana , H. , Shirouzu , K. and Itoh , K.Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA‐A24‐restricted cytotoxic T lymphocytes in cancer patients . Cancer Res. , 59 , 4056 – 4063 ( 1999. ). [PubMed] [Google Scholar]
  • 21. ) Kawano , K. , Gomi , S. , Tanaka , K. , Tsuda , N. , Kamura , T. , Itoh , K. and Yamada , A.Identification of a new endoplasmic reticulum‐resident protein recognized by HLA‐A24‐restricted tumor infiltrating lymphocytes of lung cancer . Cancer Res. , 60 , 3550 – 3558 ( 2000. ). [PubMed] [Google Scholar]
  • 22. ) Imanishi , T. , Akazawa , T. , Kimura , A. , Tokunaga , K. and Gojobori , T.Allele and haplotype frequencies for HLA and complement loci in various ethnic groups . In “ HLA, 1991 ,” Vol. 1 , ed. Tsuji K. , Aizawa M. and Sasazuki T. , pp. 1065 – 1220 ( 1992. ). Oxford Scientific Publ. , Oxford . [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES